Rosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses the results of the IND.226 trial, in an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

The primary objective of this study was to evaluate the safety and tolerability of the PD-L1 inhibitor durvalumab, with or without the CTLA-4 inhibitor tremelimumab, in combination with 1 of 4 standard platinum-doublet regimens: pemetrexed, gemcitabine, etoposide (each with cisplatin), or nab-paclitaxel (with carboplatin), in order to establish a recommended phase II dose for each combination. These particular data focus on a cohort of patients who received the pemetrexed/cisplatin treatment regimen.

The results showed that durvalumab and tremelimumab can, indeed, be safely combined with full doses of platinum-doublet chemotherapy. Seventeen out of a total of 24 PD-1 unselected patients are currently evaluable for response. The provisional objective response rate was shown to be 52.9%. Further studies assessing this combination are planned.

View more from the IASLC 17th World Conference on Lung Cancer

Rosalyn Juergens, MD, PhD

Articles

Dr. Juergens on the IND.226 Trial in Advanced Non-Squamous NSCLC